NovaDel Announces Listing on OTC Bulletin Board
December 24 2009 - 08:00AM
Business Wire
NovaDel Pharma Inc. (the “Company”) (OTCBB: NVDL) is pleased to
announce that its common stock will begin trading on the
Over-the-Counter Bulletin Board (“OTCBB”) on December 24, 2009. The
Company’s new ticker symbol on OTCBB is NVDL. The Company filed
Form 25 on December 14, 2009, voluntarily withdrawing its listing
and registration from NYSE Amex LLC (“AMEX”). The final day of
trading on AMEX was December 23, 2009.
ABOUT NOVADEL PHARMA
NovaDel Pharma Inc. is a specialty pharmaceutical company
developing oral spray formulations for a broad range of marketed
drugs. The Company’s proprietary technology offers, in comparison
to conventional oral dosage forms, the potential for faster
absorption of drugs into the bloodstream leading to quicker onset
of therapeutic effects and possibly reduced first pass liver
metabolism, which may result in lower doses. Oral sprays eliminate
the requirement for water or the need to swallow, potentially
improving patient convenience and adherence.
NovaDel’s oral spray technology is focused on addressing unmet
medical needs for a broad array of existing and future
pharmaceutical products. The Company’s most advanced oral spray
candidates target angina, nausea, insomnia, migraine headaches and
disorders of the central nervous system. NovaDel plans to develop
these and other products independently and through collaborative
arrangements with pharmaceutical and biotechnology companies. To
find out more about NovaDel Pharma Inc. (OTCBB: NVDL), visit our
website at www.novadel.com.
FORWARD-LOOKING STATEMENTS:
Except for historical information contained herein, this
document may contain forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements involve known and unknown risks and uncertainties that
may cause the Company’s actual results or outcomes to be materially
different from those anticipated and discussed herein including,
but not limited to, the ability of third parties to commercialize
the Company’s products, the successful completion of its pilot
pharmacokinetic feasibility studies, the ability to develop
products (independently and through collaborative arrangements),
the Company’s ability to obtain additional required financing to
fund its research programs, the ability to commercialize and obtain
FDA and other regulatory approvals for products under development,
and the acceptance in the marketplace for oral spray products. The
filing of an NDA with the FDA is an important step in the approval
process in the United States. Acceptance for filing by the FDA does
not mean that the NDA has been or will be approved, nor does it
represent an evaluation of the adequacy of the data submitted.
Further, the Company operates in industries where securities may be
volatile and may be influenced by regulatory and other factors
beyond the Company’s control. In addition, our inability to
maintain or enter into, and the risks resulting from our dependence
upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and
distribution of any of our products could materially impact the
Company's actual results. Important factors that the Company
believes might cause such differences are discussed in the risk
factors detailed in the Company’s most recent Annual Report on Form
10-K and Registration Statements, filed with the Securities and
Exchange Commission. In assessing forward-looking statements
contained herein, if any, the reader is urged to carefully read all
cautionary statements contained in such filings.
For more detailed information regarding NovaDel’s 2009 financial
results and its product pipeline, please review the Company’s SEC
filings on Form 10-Q at the Investor Relations section of
www.novadel.com.
Novadel (AMEX:NVD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novadel (AMEX:NVD)
Historical Stock Chart
From Mar 2023 to Mar 2024